Upside Drivers: Surpassing the 13%-15% guidance through the ramp of da Vinci 5, increased international market penetration, ...

Johnson & Johnson’s surgery and orthopedic units had solid growth to close out 2023 as procedure volumes remained stable after COVID-19 declines, potentially signaling positive reports from other ...

Despite the revenue beat, investors appeared concerned about a slowdown in Ion endoluminal system placements, which fell to 42 in the fourth quarter compared to 69 in the same period last year. The ...

Intuitive Surgical's stock is poised to return over 60% in 2024, driven by strong tailwinds in the MedTech industry and elevated capital investments. The da Vinci 5 system has been well received, with ...

For us, procedure growth is the primary factor when assessing Intuitive's competitive positioning and long-term growth prospects. Thus, we call the firm's first quarter a relative success. Procedures, ...